Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Genmab are conducting a Phase 1/2 clinical trial titled ‘A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.’ The study aims to evaluate the safety, dosage, and efficacy of epcoritamab, a promising antibody treatment for B-cell lymphoma. This trial is significant as it explores new therapeutic options for patients with limited treatment choices.
The intervention being tested is epcoritamab, a biological treatment administered via subcutaneous injections. It is designed to target and treat relapsed or refractory B-cell lymphoma.
The study follows an interventional design with a sequential intervention model and no masking, focusing primarily on treatment. Participants receive active treatment without a placebo group, ensuring direct assessment of epcoritamab’s effects.
The study began on June 26, 2018, with an estimated completion date in 2025. The primary completion date is crucial for assessing initial results, while the last update in August 2025 indicates ongoing progress.
This clinical update could influence AbbVie and Genmab’s stock performance by boosting investor confidence in their innovative cancer treatments. As the study progresses, positive results could enhance their competitive position in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.